Veru: Q2 Earnings Insights

Shares of Veru VERU remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share fell 300.00% over the past year to ($0.04), which were in line with the estimate of ($0.04).

Revenue of $13,340,000 higher by 34.16% from the same period last year, which missed the estimate of $14,290,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 12, 2021

Time: 08:00 AM

ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=VV1xc3KL

Technicals

Company's 52-week high was at $24.57

52-week low: $2.30

Price action over last quarter: down 60.22%

Company Description

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.